New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and ...

A new report from OKRs Tool reveals what actually drives OKR success inside fast-moving startups. Based on responses from over 200 early- and growth-stage companies, the 2026 OKR Benchmark Report ...

Q3 2025 Earnings Call Transcript November 4, 2025 Verastem, Inc. misses on earnings expectations. Reported EPS is $-1.35 EPS, ...

Shutterstock, Inc. (the "Company"), a family of brands delivering scalable creative and GenAI solutions to help customers fuel great work, today announced financial results for the third quarter ended ...

A live webcast of the fireside chats can be accessed under “Events & Presentations” in the Investor section of the Company’s website, https://investor.verastem.com/events. A replay of the webcasts ...

In Alzheimer's disease—the leading cause of dementia—microglia, the brain's immune defenders, can act as both protectors and ...

The management of advanced thyroid cancer requires careful consideration of histology, molecular profiling, and treatment ...

Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the ...

Parkinson's and Alzheimer's diseases are the two most common neurodegenerative disorders, affecting millions of people worldwide.

In contrast, the experts noted that several recent FDA approvals introduced first-in-class therapies to the oncology landscape. 1 Among these are menin inhibitors, which block the interaction between ...